Nanjing Leads Biolabs Co., Ltd. ("Nanjing Leads Biolabs") has introduced an H Share Award Scheme, formulated in accordance with relevant laws and regulations. The scheme will have a validity period of seven years from its date of adoption, during which no further H shares may be granted once it ends. Any grants already made before the scheme's conclusion will remain valid until vesting is completed.
Nanjing Leads Biolabs states that the goal of the scheme is to promote sustainable growth, align the interests of participants with those of shareholders, and incentivize directors, senior management, and employees who contribute to the company's long-term success. Eligible participants include company directors, employees (both full- and part-time), related entity participants, and service provider participants meeting specified criteria.
The total number of H shares under the scheme may come from new share issuances and secondary market purchases, capped at 10% of total shares in issue as of the adoption date, with a limit of 5% for newly issued shares. Within any 12-month period, no individual may receive awards exceeding 1% of the company’s total shares. Vesting periods are set at a minimum of 12 months by default, subject to discretion from the board or its delegates in approved situations.
Management of the scheme, including grants, vesting schedules, adjustments, and distribution of dividends, is handled by the board or delegated authorities according to the rules. Participants are prohibited from transferring or pledging unvested shares. In circumstances such as termination of employment on serious grounds, all unvested shares will lapse. The scheme will also end prematurely if a resolution for early termination is passed, at which time no further awards will be granted and unvested shares will be handled by the appointed trustee in accordance with specified procedures.
Comments